(Q42633635)

English

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

scientific article published on 24 January 2012

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Tudor Ciuleanu

1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Lilia Stelmakh

2

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Saulius Cicenas

3

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Skaidrius Miliauskas

4

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Alexandru Calin Grigorescu

5

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Carina Hillenbach

6

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Hrefna Kristin Johannsdottir

7

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Barbara Klughammer

8

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Emilio Esteban Gonzalez

9

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

publication date

24 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

300-308

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970385-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970385-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970385-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970385-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970385-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970385-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970385-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970385-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970385-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970385-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970385-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970385-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970385-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970385-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970385-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970385-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70385-0

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42633635&oldid=1963865845"